News | Image Guided Radiation Therapy (IGRT) | April 30, 2018

ViewRay Unveils New Soft Tissue Visualization Technologies for MRIdian Linac

New MR pulse sequences and imaging enhancements provide cutting-edge tumor and healthy tissue visualization for MR-guided radiotherapy

ViewRay Unveils New Soft Tissue Visualization Technologies for MRIdian Linac

April 30, 2018 — ViewRay Inc. announced new magnetic resonance imaging (MRI) technologies under development for its MRIdian Linac radiotherapy system. Designed to improve tumor and soft tissue visualization, these enhancements to MRIdian's SmartVision MR image guidance are expected to further improve the precision by which radiation is delivered to treat cancer.

MRIdian's SmartVision allows oncologists to visualize tumors and surrounding organs with diagnostic-quality MR imaging during treatment delivery. Building on the current technology are new T1w and T2w MR pulse sequences, both being developed to improve high-definition visualization and enhance the contrast between cancerous and healthy tissues. Also being developed for MRIdian's SmartVision, diffusion weighted imaging (DWI) may be used to distinguish between tumor and normal tissues and potentially assess and predict tumor response to radiation therapy.

Other enhancements to MRIdian's SmartVision include a 2-times increase in MR imaging speed as compared to previous generation systems, stepping up from 4 frames to 8 frames per second. The latest enhancements under development also include 2 times higher image resolution and a 2 times improvement in MR signal-to-noise ratio (SNR) for brighter, more detailed anatomical imaging.

MRIdian continuously detects the shape and location of tumors and organs-at-risk (OAR) in real-time, and automatically turns radiation beams on and off when positional changes occur. Enabled by faster, higher-resolution imaging, the next-generation SmartVision will further support the clinician's ability to visualize healthy tissue and target the tumor.

ViewRay demonstrated the new MR pulse sequences, along with increased imaging speed and resolution, during the annual meeting of the European Society for Radiotherapy and Oncology (ESTRO), April 21-24 in Barcelona, Spain.

The new pulse sequences, increased image resolution and imaging frame rates are currently a technology under development and only available for sales in the European Economic Area. They are works in progress and are not available for commercial sales in the United States.

For more information: www.viewray.com

 

Related Content

Ingenia Ambition X 1.5T MR. This innovation is the latest advance in the Ingenia MRI portfolio, which comprises fully-digital MRI systems, healthcare informatics and a range of maintenance and life cycle services for integrated solutions that empower a faster, smarter, and simpler path to enabling a confident diagnosis
News | Magnetic Resonance Imaging (MRI) | September 14, 2018
Philips, a global leader in health technology, launched the Ingenia Ambition X 1.5T MR.
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Veye Chest version 2
News | Lung Cancer | September 11, 2018
Aidence, an Amsterdam-based medical AI company, announced that Veye Chest version 2, a class IIa medical device, has
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...
Sponsored Content | Case Study | Magnetic Resonance Imaging (MRI) | September 07, 2018 | By Sabine Sartoretti, M.D.
As soon as the Compressed SENSE technology became available to the MRI team at Kantonsspital Winterthur (Switzerland),...

Image courtesy of Philips Healthcare

Feature | Magnetic Resonance Imaging (MRI) | September 06, 2018 | By Melinda Taschetta-Millane
According to the Prescient & Strategic Intelligence report, “Global Magnetic Resonance Imaging (MRI) Market Size,...
Brain Iron Levels May Predict Multiple Sclerosis Disabilities
News | Neuro Imaging | August 31, 2018
A new, highly accurate magnetic resonance imaging (MRI) technique can monitor iron levels in the brains of multiple...
Study Finds Multiple Sclerosis Drug Slows Brain Shrinkage

An NIH-funded clinical trial suggested that the anti-inflammatory drug ibudilast may slow brain shrinkage caused by progressive MS. Image courtesy of Robert J. Fox, M.D., Cleveland Clinic.

News | Neuro Imaging | August 30, 2018
August 30, 2018 — Results from a clinical...
Non-Canonical Strategy May Improve Cancer Radiotherapy
News | Radiation Therapy | August 29, 2018
August 29, 2018 — Although the success or failure of...
Overlay Init